Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, prospective, randomized controlled study to compare the efficacy of Ustekinumab with tumor necrosis factor inhibitor in clearing enthesitis in Psoriatic arthritis patients

Next Previous
Trial Profile

An open label, prospective, randomized controlled study to compare the efficacy of Ustekinumab with tumor necrosis factor inhibitor in clearing enthesitis in Psoriatic arthritis patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms ECLIPSA

Most Recent Events

  • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
  • 07 Jul 2017 New trial record
  • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top